MISC

2007年5月

Formalin-treated UV-inactivated SARS coronavirus vaccine retains its immunogenicity and promotes Th2-type immune responses

JAPANESE JOURNAL OF INFECTIOUS DISEASES
  • Yasuko Tsunetsugu-Yokota
  • Manabu Ato
  • Yoshimasa Takahashi
  • Shu-ichi Hashimoto
  • Tomohiro Kaji
  • Masayuki Kuraoka
  • Ki-ichi Yamamoto
  • Yu-ya Mitsuki
  • Takuya Yamamoto
  • Masamichi Oshima
  • Kazuo Ohnishi
  • Toshitada Takemori
  • 全て表示

60
2-3
開始ページ
106
終了ページ
112
記述言語
英語
掲載種別
出版者・発行元
NATL INST INFECTIOUS DISEASES

The demand for rapid and simple development of a vaccine against a newly emerging infectious disease is increasing worldwide. We previously revealed that UV-inactivated severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) virions (UV-V) elicited high levels of humoral immunity and a weak ThO response in mice immunized subcutaneously. To ensure the safety of such a whole inactivated SARS-CoV vaccine, we additionally treated the UV-V vaccine with formalin, resulting in the UV-F-V vaccine. Analysis of the immunogenicity of the UV-F-V+alum vaccine in mice revealed that it generated comparable neutralizing serum anti-SARS-CoV IgG antibody levels as the UV-V+alum vaccine. Moreover, both vaccines induced similar frequencies of anti-SARS-CoV IgG antibody-producing cells in bone marrow. Interestingly, the UV-F-V vaccine induced fewer IgG(2a) subtype antibodies and higher interleukin-4 production in vaccinated mice than did UV-V. Thus, UV-F-V imposes a Th2-type bias on the immune response, unlike UV-V. We propose here that doublyinactivated SARS-CoV virions by UV and fon-nalin constitute a safe vaccine that may effectively induce neutralizing antibodies in humans.

リンク情報
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000246892200008&DestApp=WOS_CPL
ID情報
  • ISSN : 1344-6304
  • eISSN : 1884-2836
  • Web of Science ID : WOS:000246892200008

エクスポート
BibTeX RIS